Skip to main content
23 search results for:

Temozolomide 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-10-2019 | Small-cell lung cancer | News | Article

    Olaparib–temozolomide combination has ‘substantial’ activity in relapsed SCLC

    A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.

  2. 22-08-2017 | Glioma | News | Article

    Adjuvant temozolomide recommended for non-co-deleted anaplastic glioma

    Adjuvant temozolomide chemotherapy significantly improves survival in patients with non-co-deleted anaplastic glioma, and should now be considered the standard of care in these patients, say the CATNON trial investigators.

  3. 21-03-2017 | Glioblastoma multiforme | News | Article

    Temozolomide improves short-course radiotherapy outcome in glioblastoma

    Adding temozolomide to short-course radiotherapy significantly increases overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, phase III trial data show.

  4. 14-08-2017 | Glioblastoma multiforme | Article

    Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

    This phase II study shows that bevacizumab plus bi-weekly temozolomide is well tolerated by adult patients with recurrent glioblastoma, and could be considered as an additional salvage therapy. Badruddoja BA et al. Cancer Chemother Pharmacol 2017. doi:10.1007/s00280-017-3405-7

  5. 21-10-2016 | Glioblastoma multiforme | Article

    Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma

    In this retrospective comparative effectiveness study, Arvold et al. demonstrate that temozolomide plus radiotherapy, a standard treatment for glioma, exerts a minimal survival benefit in older patients with glioblastoma. Arvold ND et al. J Neurooncol 2017; 131: 301–311. doi:10.1007/s11060-016-2294-7

  6. 02-02-2016 | Glioblastoma multiforme | Article

    Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component

    To address the lack of standardized treatment for glioblastoma with elements of primitive neuroectodermal tumor, O’Leary et al. investigate whether craniospinal irradiation with temozolomide presents a viable treatment option. O’Leary B et al. J Neurooncol 2016; 127: 295–302. doi:10.1007/s11060-015-2033-5

  7. 27-08-2018 | Glioma | News | Article
    News in brief

    Bevacizumab strikes out in recurrent glioma

    The outcomes of patients with a first recurrence of WHO grade II or III glioma without the 1p/19q co-deletion are not improved when bevacizumab is added to the standard of care temozolomide, suggest phase II trial findings.

  8. 21-02-2018 | Glioma | News | Article

    No event-free survival benefit with bevacizumab in pediatric high-grade glioma

    Adding bevacizumab to radiotherapy plus temozolomide does not improve event-free survival in children with newly diagnosed high-grade glioma, trial findings show.

  9. 09-02-2018 | Glioblastoma multiforme | News | Article

    QoL not diminished by tumor-treating fields therapy for glioblastoma

    Adding tumor-treating fields to standard treatment with temozolomide does not negatively affect health-related quality of life in patients with newly diagnosed glioblastoma, an analysis of EF-14 data shows.

  10. 21-12-2017 | Glioblastoma multiforme | News | Article

    Tumor-treating fields therapy benefits patients with glioblastoma

    Adding tumor-treating fields therapy to standard temozolomide maintenance significantly delays disease progression and improves survival in patients with newly diagnosed glioblastoma, phase III trial data show.

  11. 25-04-2017 | Glioblastoma multiforme | News | Article

    Glioblastoma survival benefit with vaccination, chemotherapy combination

    Treatment with a cytomegalovirus-targeted dendritic cell-based vaccine together with dose-intensified temozolomide leads to improved survival in patients with newly diagnosed glioblastoma relative to historic controls given standard therapy, findings indicate.

  12. 01-03-2017 | Glioblastoma multiforme | Article

    Multilesion glioblastoma multiforme in the modern chemo-radiotherapy era: An analysis of pattern of failure and overall survival

    This retrospective study of newly diagnosed glioblastoma patients highlights a variance in overall survival following modern chemo-radiotherapy despite similar patterns of disease progression. Trifiletti DM et al. J Radiat Oncol 2017; 6: 57–63. doi:10.1007/s13566-017-0297-4

  13. 29-12-2016 | Glioblastoma multiforme | Book chapter | Article

    Glioblastoma

    This chapter summarizes the approaches to glioblastoma screening, diagnosis and staging and a future outlook. Wirsching HG, Weller M. In: Malignant Brain Tumors . Edited by Gunel JM et al. Springer International Publishing, 2016. doi:10.1007/978-3-319-49864-5_18

  14. 11-09-2017 | Glioblastoma multiforme | ESMO 2017 | Article
    ESMO 2017

    Regorafenib improves outcomes in relapsed glioblastoma patients

    OS was a median of 6.5 months for the 59 patients with disease recurrence after treatment with radiation plus temozolomide who were randomly assigned to receive regorafenib 160 mg/day for 3 weeks followed by a 1 week break.

  15. 25-08-2017 | Checkpoint blockade | News | Article
    News in brief

    Equine anti-thymocyte globulin could be an option for immunotherapy-related myocarditis

    The patient – a 64-year-old woman with IDH -wild-type glioblastoma – developed malignant arrhythmias secondary to severe immune-mediated myocarditis during treatment with nivolumab, temozolomide, and radiation.

  16. 09-03-2017 | Lymphoma | Case report | Article

    CNS lymphoma

    Use of other chemotherapeutic agents with CNS penetration such as high-dose cytarabine, etoposide, and/or temozolomide, if not administered previously, can be considered.

  17. 26-06-2017 | PARP inhibitors | Article

    Synthetic lethality and cancer

    For example, in glioblastoma cell lines that contain mutations in the cohesin component  STAG2 , PARP inhibition resulted in synthetic cytotoxicity in response to the DNA-damaging chemotherapeutic temozolomide 29 .

  18. 13-10-2016 | PARP inhibitors | Article

    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: Current practice and future directions

    In contrast, in the present phase I trial that combined talazoparib with temozolomide, the PARP inhibitor dose was kept high from the onset at a dose with proven single agent activity, and the temozolomide dose was started at a low dose and carefully escalated until an MTD was reached.

  19. 02-03-2017 | Liquid biopsy | Review | Article

    Integrating liquid biopsies into the management of cancer

    Of note, MGMT silencing by promoter methylation has been used to identify patients with GBM or metastatic colorectal cancer who are most likely to respond to the alkylating agents dacarbazine or temozolomide 145 .

  20. 12-08-2016 | Acute lymphoblastic leukemia | Article

    A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

    Temozolomide induced regressions in 5/8 ALL PDXs at its murine maximum tolerated dose, however, the activity of the drug steeply declined upon dose attenuation to achieve exposure levels comparable to those in humans. 19 Mitotic inhibitors The antimitotic agent eribulin and the kinesin spindle protein inhibitor ispinesib were highly effective against the ALL PDXs. 35, 70 Eribulin elicited objective responses in 8/8 PDXs (2 CRs, 6 MCRs) against the ALL panel, whereas ispinesib achieved objective responses in 4/6 PDXs (2 PRs, 2 CRs).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.